Navigation Links
Blood sugar improves with first gastrointestinal microbiome modulator, NM504
Date:6/23/2014

CHICAGO, IL In adults with prediabetes, a new drug that alters microbial populations and their environment in the gastrointestinal (GI) tract improves glucose tolerancethe body's response to consuming carbohydrates after four weeks of treatment and without a change in diet. These results, from a pilot study, will be presented Monday at the joint meeting of the International Society of Endocrinology and the Endocrine Society: ICE/ENDO 2014 in Chicago.

The not-yet-named therapeutic, NM504, is the first in a new class of therapies known as GI microbiome modulators. The GI microbiomethe mix of microbial and associated physical and chemical factors in the digestive systemmay play a critical part in regulating the body's metabolism, some researchers believe. There is recent scientific evidence that microbial imbalance, or dysbiosis, in the gut contributes to the development of Type 2 diabetes.

"We believe that modern Western diets contribute to development of Type 2 diabetes, in part because they change the habitat of the microorganisms that reside in the gut. This shifts the microbial populations that live there in ways that affect metabolic health," said Mark Heiman, PhD, the study's principal investigator. Heiman is chief scientific officer for MicroBiome Therapeutics, the Colorado-based biotechnology company that is developing NM504 and sponsored the study.

NM504 is designed to shift the GI bacteria and other microorganismscalled microbiotaand their environment in specific ways to achieve improved health outcomes, according to Heiman. He said the drug contains concentrated bioactive food ingredients: inulin, a fiber; beta-glucan and polyphenolic antioxidant compounds.

Heiman and colleagues conducted a study in 28 adults with prediabetes, a frequent precursor to Type 2 diabetes. Fourteen subjects were randomly assigned to receive NM504 twice a day, and the other 14 were assigned to receive placebo, or "dummy" material. Neither the subjects nor the investigators were aware of the drug assignments. Before any treatment and again at four weeks of treatment, all subjects had an oral glucose challenge. In this test, they drank a concentrated glucose (sugary) drink and then had their blood sugar levels tested at various times and compared with pretest levels.

Blood sugar levels at 120 and 180 minutes after the glucose challenge were significantly lower in subjects who took NM504 than those who received the placebo, Heiman reported. Also during this test, NM504 increased insulin sensitivity, the body's ability to successfully clear glucose from the bloodstream.

Compared with placebo, NM504 treatment also decreased the desire to eat, which Heiman said Microbiome Therapeutics' researchers had hoped the therapeutic would do. He said the subjects tolerated NM504 well, with only a mild increase in flatulence, or gas.

"This work indicates a new therapeutic targetthe GI microbiomethat has the potential to revolutionize the treatment of metabolic diseases such as Type 2 diabetes," Heiman commented.

MicroBiome Therapeutics reports that the company plans to develop NM504 and/or a closely related therapeutic as a prescription medicine to treat prediabetes and diabetes.


'/>"/>
Contact: Aaron Lohr
alohr@endocrine.org
202-971-3654
The Endocrine Society
Source:Eurekalert

Related medicine news :

1. Infection Might Raise Blood Clot Risk for Older Adults: Study
2. Normalizing tumor blood vessels improves delivery of only the smallest nanomedicines
3. Common Blood Pressure Drug Safe for Heart Failure: Study
4. Certain Birth Control Pills May Carry Higher Blood Clot Risk: FDA
5. High Blood Pressure May Be Especially Lethal for Blacks
6. Changes in gene expression may help explain high blood pressure in pregnancy
7. Researchers Develop Blood Test for Depression
8. Naturopathic care can improve blood sugar, mood in diabetes
9. Diabetes Groups Issue New Guidelines on Blood Sugar
10. Exercise May Help Patients With High Blood Pressure Live Longer
11. Additional blood pressure screening may reduce incidence of CVD events and death by up to 3 percent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/14/2019)... SEATTLE (PRWEB) , ... November 14, 2019 , ... ... non-invasive treatments for cancers and other serious diseases, announced it will have 5 ... cancers at the upcoming 24th Annual Society for Neuro-Oncology SNO Meeting in Phoenix, ...
(Date:11/14/2019)... ... November 14, 2019 , ... With winter just around the corner, parents want to make sure ... and overalls might keep little ones warm, during a car ride they can become dangerous, ... must fit snugly in order to ensure maximum safety during a crash or sudden stop. ...
(Date:11/12/2019)... (PRWEB) , ... November 12, 2019 , ... ... and health systems, today announced that Tidewater Physicians Multispecialty Group (TPMG), ... selected the Healthy Outcomes® patient engagement platform to deliver enhanced patient ...
(Date:11/11/2019)... ... November 11, 2019 , ... Early praise for A Nurse’s Step-by-Step Guide to ... scholarly writing and provides key insight and vital guidance for publishing dissertations or DNP ... a permanent place on my bookshelf and will be shared with new graduates and ...
(Date:11/11/2019)... ... November 11, 2019 , ... Last year’s expo was a resounding ... big box buyers like Costco, Walmart, and GNC. Exhibitors included some of the ... few. , This year, CBD.io and partners, are once again set ...
Breaking Medicine News(10 mins):
(Date:11/14/2019)... , ... November 14, 2019 , ... ... size of a Band-Aid that will measure a baby’s blood oxygen levels, a ... adequate oxygen supply. Unlike current systems used in hospitals, this miniaturized wearable device ...
(Date:11/14/2019)... YORK (PRWEB) , ... November 14, 2019 , ... ... brand, K-FISH, aimed to promote the quality of Korean seafood and enhance its ... promotions entitled, "K-Seafood Global Weeks" in many countries. These special events are ...
(Date:11/11/2019)... ... November 11, 2019 , ... Attorneys representing an ... statement before U.S. Bankruptcy Court Judge Robert Drain in White Plains, NY notifying ... prescription opioid epidemic cannot be forgotten as a $12 billion settlement is considered. ...
Breaking Medicine Technology: